Nasonex (Mometasone Furoate)

Mometasone furoate is a potent glucocorticoid that binds to intracellular glucocorticoid receptors in the nasal mucosa. This binding alters gene expression, suppressing the release of inflammatory mediators such as cytokines and prostaglandins, which reduces swelling and mucus production.

The exact dosing regimen for Nasonex is determined by the prescribing healthcare professional. In typical practice, adults may receive one spray per nostril once daily, but the prescriber will adjust the dose based on the patient’s age, severity of symptoms, and response to therapy.

The safety of Nasonex during pregnancy and lactation has not been definitively established. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and this decision must be made in consultation with a qualified healthcare provider.

To order Nasonex, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Nasonex (mometasone furoate) is a high‑potency nasal corticosteroid with a once‑daily dosing schedule, similar to fluticasone propionate and budesonide. Clinical studies suggest comparable efficacy in reducing allergic rhinitis symptoms, while its formulation may offer a lower incidence of taste alteration for some patients.

Store Nasonex at room temperature, below 25 °C. Keep the bottle in its original packaging, protect it from moisture and direct heat, and ensure the spray tip remains clean to maintain product integrity.

Nasonex is administered as a nasal spray. The user should gently blow the nose, tilt the head slightly forward, insert the nozzle into one nostril, close the opposite nostril, and press the pump while breathing in gently through the nose. Repeat in the other nostril if prescribed.

Serious risks include nasal septal perforation, severe allergic reactions such as anaphylaxis, adrenal suppression with prolonged high‑dose use, and opportunistic fungal infections of the nasal cavity. Patients should seek immediate medical attention if they experience unusual bleeding, persistent ulceration, or systemic symptoms.

Nasonex should not be used by individuals with known hypersensitivity to mometasone furoate or any component of the formulation, and it is contraindicated in patients with untreated bacterial, fungal, or viral nasal infections. Caution is also advised for children below the approved age range and for patients with uncontrolled glaucoma.